Examkin

Soru

Zorluk: OrtaBreast and Endocrine Surgery

Match each patient's clinical presentation and breast pathology findings with the most appropriate surgical or overall management strategy.

  • A 32-year-old woman with a 1.5-cm, mobile, non-tender breast mass. Core needle biopsy confirms a fibroadenoma. She prefers to avoid surgery if possible.Clinical observation and routine screening
  • A 55-year-old woman diagnosed with a 2-cm unifocal invasive ductal carcinoma. Her axilla is clinically negative, and she strongly desires to preserve her breast.Breast-conserving surgery (lumpectomy) with sentinel lymph node biopsy and subsequent adjuvant radiation
  • A 60-year-old woman with a 3-cm invasive carcinoma. Mammography reveals extensive pleomorphic microcalcifications involving three different breast quadrants.Total (simple) mastectomy with sentinel lymph node biopsy
  • A 45-year-old woman diagnosed with a 3-cm invasive ductal carcinoma. She has fixed, matted axillary lymph nodes that are biopsy-proven for metastasis.Neoadjuvant chemotherapy followed by breast surgery and completion axillary lymph node dissection
  • A 38-year-old woman presenting with rapidly progressing diffuse breast erythema and peau d'orange. Biopsy confirms invasive carcinoma with dermal lymphatic invasion.Neoadjuvant systemic chemotherapy followed by modified radical mastectomy and post-mastectomy radiation

Cevap

The correct pairings match each specific breast pathology to its definitive guideline-directed management: observation for benign asymptomatic fibroadenomas, lumpectomy for localized disease, mastectomy for multicentric disease, axillary dissection for fixed positive nodes, and neoadjuvant chemotherapy for inflammatory breast cancer.
Each specific clinical scenario dictates a distinct guideline-directed management pathway. Fibroadenomas in asymptomatic patients who do not desire surgery can be safely observed. Early-stage, unifocal breast cancer is ideally treated with breast-conserving therapy (lumpectomy plus radiation) if the patient desires breast preservation and has no contraindications. Multicentric disease (involving multiple quadrants) is an absolute contraindication to breast-conserving therapy, mandating a mastectomy. Patients with clinically positive, fixed or matted axillary lymph nodes require neoadjuvant chemotherapy to downstage the disease, followed by a formal axillary lymph node dissection rather than a sentinel node biopsy. Finally, inflammatory breast cancer (characterized by dermal lymphatic invasion and peau d'orange) is never treated with upfront surgery; it requires immediate neoadjuvant chemotherapy followed by modified radical mastectomy.

Adım Adım Çözüm

1
Evaluate the pathology and extent of disease in each patient scenario.
Identified benign (fibroadenoma), early localized, multicentric, node-positive, and inflammatory presentations.
Definitive surgical indications depend primarily on tumor size, focality, nodal status, and inflammatory features.
2
Determine contraindications for breast-conserving therapy (BCT).
The scenario with extensive microcalcifications across three quadrants has multicentric disease, an absolute contraindication to BCT, thus requiring mastectomy.
BCT requires the ability to achieve clear margins and deliver post-operative radiation without excessive cosmetic failure.
3
Assess indications for upfront systemic therapy.
The patients with fixed axillary nodes and inflammatory breast cancer both require neoadjuvant chemotherapy before any surgical intervention.
Locally advanced and inflammatory breast cancers require systemic downstaging to improve survival and resectability prior to operative management.

Anahtar Kavram

Surgical and Neoadjuvant Management of Breast Disease
Tahmini Süre:2m 0s
Bu soruyu puanla

Konular

Breast and Endocrine Surgery

Bu konudan daha fazla soru